Clinical value of umbilical cord mesenchymal stem cells transplantation in the treatment of acute spinal cord injury

English Keywords:Acute spinal cord injury  Umbilical cord mesenchymal stem cells  Transplantation  Functional recovery

English Abstract:

  【Abstract】 Objectives: To discuss the clinical value of umbilical cord mesenchymal stem cells(UC-MSC) transplantation in the treatment of patients with acute spinal cord injury(ASCI). Methods: 50 ASCI patients were selected as research group in our hospital from January 2017 to January 2018, while 50 ASCI patients were selected as control group in the same period. All the patients were carried out decompression and internal fixation within 72 hours after damaged, the patients were given the conventional treatment of anti-inflammatory, dehydration, anti-infection and neurotrophy in control group, the patients were injected umbilical cord mesenchymal stem cells by intravenous infusion combined with lumbar puncture based on conventional treatment in research group. The functional recovery index(ASIA grade and score, Botsford and FIM score), T cell subset(CD3+, CD4+, CD8+, CD4+/CD8+) and immune globulin(IgG, IgA, IgM) were compared between two groups before treatment and in the third, sixth, twelfth month after treatment. And the untoward effect(encephalalgia, fever, gastrointestinal dysfunction, urinary tract infection) was observed. Results: In the third, sixth, twelfth month after treatment, the ASIA grade improvement rate, ASIA movement score, ASIA sensory score, Botsford score and SCIM-Ⅲ score significantly increased continually in two groups(P<0.05), the level of CD3+, CD4+, CD4+/CD8+ significantly decreased continually in two groups(P<0.05), the level of CD8+ and level of IgG, IgA, IgM were not significantly changed in two groups(P>0.05). The ASIA grade improvement rate, ASIA movement score, ASIA sensory score, Botsford score and SCIM-Ⅲ score of research group were higher than those of control group(P<0.05), there was no statistical significance on the level of CD3+, CD4+, CD8+, CD4+/CD8+, IgG, IgA, IgM between two groups(P>0.05). The occurrence rate of untoward effect was 18.0% and 14.0% in research group and control group, respectively and there was no statistical significance between the two groups(P>0.05). Conclusions: Umbilical cord mesenchymal stem cells could obviously promote the functional recovery of ASCI patients, and it did not affect the humoral immunity and increase the untoward effect.